Abstracts tagged "Bone density"

Abstract Number: 2312 • 2018 ACR/ARHP Annual Meeting
Spontaneous Vertebral Fractures after Denosumab Discontinuation
Helena Florez¹, Julio Ramírez², Ana Monegal¹, Núria Guañabens¹ and Pilar Peris¹, ¹Department of Rheumatology, Hospital Clinic, University of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain
Spontaneous Vertebral Fractures after Denosumab Discontinuation.H. Florez, J. Ramírez, A. Monegal, N. Guañabens, P. Peris. Department of Rheumatology. Hospital Clinic, University of Barcelona. Background/Purpose: Denosumab…
Abstract Number: 2315 • 2018 ACR/ARHP Annual Meeting
Opportunistic Screening for Osteoporosis Using Thoraco-Abdomino-Pelvic Computed Tomography Assessing the Vertebral Density in Rheumatoid Arthritis Patients
Julia Perrier-Cornet¹, Abdou Yacoubou OMOUROU², Marine FAUNY¹, Damien Loeuille³ and Isabelle Chary-Valckenaere⁴, ¹Rheumatology, University Hospital of Nancy, VANDOEUVRE LES NANCY, France, ²Inserm, CIC-1433 Clinical Epidemiology, University Hospital of Nancy, VANDOEUVRE LES NANCY, France, ³Rheumatology, University Hospital of Nancy, NANCY, France, ⁴Rheumatology, CHRU Nancy, Vandoeuvres les Nancy, France
Background/Purpose: Screening for osteoporosis is crucial in rheumatoid arthritis (RA) patients. The aim of this study was to assess the value of thoraco-abdomino-pelvic CT-derived bone…
Abstract Number: 2322 • 2018 ACR/ARHP Annual Meeting
Intervals of Bone Mineral Density Measurement during Treatment for Osteoporosis in Patients with Rheumatoid Arthritis
Seung Yun Lee¹, Seong Ryul Kwon¹, Mie Jin Lim², Kyong-Hee Jung³ and Won Park⁴, ¹Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, Korea, Republic of (South), ²Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheon, Korea, Republic of (South), ³Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), ⁴Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South)
Background/Purpose: There is controversy about the intervals of retesting bone mineral density (BMD) in patients treated for osteoporosis. The objective of this study is to…
Abstract Number: 318 • 2017 ACR/ARHP Annual Meeting
A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
Kenneth Saag¹, Jeffrey Petersen², Maria Luisa Brandi³, Andrew Karaplis⁴, Mattias Lorentzon⁵, Thierry Thomas⁶, Judy Maddox², Michelle Fan², Paul D. Meisner⁷ and Andreas Grauer², ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³University of Florence, Florence, Italy, ⁴McGill University, Montreal, QC, Canada, ⁵University of Gothenburg and Sahlgrenska University Hospital, Mölndal, Sweden, ⁶CHU de Saint-Étienne, Saint-Étienne, France, ⁷UCB Pharma, Brussels, Belgium
Background/Purpose: The bone forming agent romosozumab (Romo) was previously shown to reduce vertebral and clinical fractures in postmenopausal women with osteoporosis. Here we report the…
Abstract Number: 2514 • 2017 ACR/ARHP Annual Meeting
When Should Lateral Dexa be Used to Measure Spine Bone Mineral Density in Axial Spondyloarthritis Patients: A Cross-Sectional Study
Sizheng Zhao^1,2, Daniel Thong³, Eleanor Quilliam², Stephen Duffield¹, Kai-Wei Yin³ and Nicola Goodson^1,2, ¹Musculoskeletal Biology 1 Department, University of Liverpool, Liverpool, United Kingdom, ²Aintree University Hospital, Liverpool, United Kingdom, ³University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Osteoporosis and vertebral fractures are recognized complications in axial spondyloarthritis (axSpA). Anteroposterior (AP) DEXA is commonly used to assess spinal bone mineral density (BMD)…
Abstract Number: 324 • 2017 ACR/ARHP Annual Meeting
The Predictors of the Efficacy of Denosumab, a Monoclonal Antibody to RANK Ligand, on Osteoporosis in Rheumatoid Arthritis Patients from Japanese Multicenter Study
Kyosuke Hattori¹, Yuji Hirano¹, Yasuhide Kanayama², Nobunori Takahashi³, Naoki Ishiguro³ and Toshihisa Kojima³, ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Although early intensive treatment has improved medication of rheumatoid arthritis (RA), treatment for osteoporosis (OP) in RA patient will be more important. Here, we…
Abstract Number: 2911 • 2017 ACR/ARHP Annual Meeting
Low Appendicular Bone Mass Predicts Mortality in Patients with Rheumatoid Arthritis
Mark Edward Hall¹, Inmaculada del Rincon², Jose Felix Restrepo², Daniel F. Battafarano³, Jakob Algulin⁴ and Agustin Escalante², ¹Internal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Internal Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Medicine, San Antonio Military Medical Center, San Antonio, TX, ⁴Sectra AB, Linköping, Sweden
Background/Purpose: Rheumatoid Arthritis (RA) is a multi-system disease which causes joint damage and is associated with increased cardiovascular (CV) morbidity and osteoporosis. Our purpose is…
Abstract Number: 330 • 2017 ACR/ARHP Annual Meeting
Change in Bone Mineral Density in Patients with Rheumatoid Arthritis: Minimal 10-Year Follow-up
Hiraku Motomura, Isao Matsushita, Toshihito Hiraiwa and Tomoatsu Kimura, Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: To investigate the long-term change in bone mineral density (BMD) in patients with rheumatoid arthritis (RA). Methods: In a longitudinal study of 40 patients…
Abstract Number: 331 • 2017 ACR/ARHP Annual Meeting
Case Series: Comparison of Repository Corticotropin Injection (H.P. Acthar Gel) Versus Glucocorticoids on Bone Density in SLE Patients
Anny T. Wu¹ and Joshua June², ¹Rheumatology, Franciscan Alliance, Munster, IN, ²3394 E Jolly Rd Ste C, Great Lakes Center of Rheumatology, Lansing, MI
Background/Purpose: Repository Corticotropin Injection (RCI) is an adrenocorticotropin hormone in 16% gelatin with a prolonged release after intramuscular (IM) or subcutaneous injection. Adverse effects of…
Abstract Number: 334 • 2017 ACR/ARHP Annual Meeting
Comparison of Outcomes in Osteoporosis in Patients on Denosumab between Standard and Non-Standard Dosing Intervals
Nouman A. Syed, Mohammed Wiqar, Douglas Einstadter and Marina N. Magrey, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Denosumab (Dmab) is an antiresorptive agent with an approximate half-life of 26 days and according to the prescribing information the recommended dose is 60…
Abstract Number: 1218 • 2017 ACR/ARHP Annual Meeting
Caffeine Consumption and Risk of Osteoporosis: A Cross Sectional Study of 3, 210 Patients from the National Health and Nutrition Examination Survey
Nicola Berman¹, Teresa Attina², Bruce Cronstein¹, Stephen Honig¹ and Michael Pillinger¹, ¹Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ²Pediatrics, New York University School of Medicine, New York, NY
Background/Purpose: Adenosine regulates bone metabolism. In vitro studies suggest that direct stimulation of the adenosine A2A receptor increases osteoblasts and diminishes osteoclasts, and thus inhibition…
Abstract Number: 1222 • 2017 ACR/ARHP Annual Meeting
Impact of Bariatric Surgery on Bone Mineral Density : Observational Study of 110 Patients Followed up in a Specialised Centre for the Treatment of Obesity in France
Marion Geoffroy¹, Isabelle Lambrecht¹, Jan Chrusciel², Isabelle Gaubil-Kaladjian³, Ana Diaz-Cives⁴, Jean Paul Eschard¹ and Jean-Hugues Salmon¹, ¹Service de Rhumatologie, CHU Reims, Hôpital Maison Blanche, Reims, France, ²Service de Recherche Clinique, CHU Reims, Hôpital Robert Debré, Reims, France, ³Service d’Endocrinologie et nutrition, CHU Reims, Hôpital Robert Debré, Reims, France, ⁴Service de chirurgie digestive, CHU Reims, Hôpital Robert Debré, Reims, France
Background/Purpose: Bariatric surgery is used to treat severe obesity. We aimed to investigate the incidence of significant bone mineral density (BMD) loss at 6 and…
Abstract Number: 1223 • 2017 ACR/ARHP Annual Meeting
Inflammatory Bowel Diseases and the Risks of Fracture and Low Mineral Density: Review of the Literature and Meta-Analysis of Observational Cohorts
Paulina Szafors¹, Thomas Barnetche², Cédric Lukas³, Jacques Morel⁴, Cécile Gaujoux-Viala^5,6, Bernard Combe⁷ and Hélène Che⁸, ¹Department of Rheumatology, Lapeyronie Hospital and University of Montpellier, Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ⁵Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁶EA 2415, Montpellier University, Nîmes, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁸Rheumatology, University and Hospital Lapeyronie, University of Montpellier, France
Background/Purpose: Inflammatory bowel diseases (IBD), such as Crohn disease (CD) and ulcerative colitis (UC), are associated with a decreased bone mineral density caused by chronic…
Abstract Number: 1228 • 2017 ACR/ARHP Annual Meeting
Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture
Anna Lafian¹, Julia Suh² and Karina Torralba³, ¹Internal Medicine, Arrowhead Regional Medical Center, Colton, CA, ²Internal Medicine, Loma Linda University, Loma Linda, CA, ³Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: Postmenopausal women with breast cancer have higher osteoporosis risk due to declining estrogen levels and use of aromatase inhibitors (AIs). The American Society of…
Abstract Number: 1886 • 2017 ACR/ARHP Annual Meeting
Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
E Michael Lewiecki¹, Rajani V Dinavahi², Marise Lazaretti-Castro³, Peter R Ebeling⁴, J Adachi⁵, Akimitsu Miyauchi⁶, Evelien Gielen⁷, Cassandra E Milmont², Cesar Libanati⁸ and Andreas Grauer², ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of São Paulo, São Paulo, Brazil, ⁴Monash University, Melbourne, Australia, ⁵McMaster University, Hamilton, ON, Canada, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷University Hospitals Leuven, Leuven, Belgium, ⁸UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is a monoclonal antibody that binds sclerostin with a dual effect, increasing bone formation and decreasing bone resorption. In the primary analysis…

« Previous Page
1
…
8
9
10
11
12
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].